Level C· Early human research exploring benefitsProspective StudyPubMed

3D-Cultured Mesenchymal Stem Cell-Derived Exosomes Embedded in a Hybrid Scaffold Enhance Diabetic Wound Healing by Promoting Angiogenesis.

Jiang L., Su H., Zhao H., Xu W., Zhang Y., Liu B.

Prospective Study on Diabetic Foot, Chronic Wound, published in FASEB J (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
FASEB J (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41511155
DOI
10.1096/fj.202503039R

Abstract (original English)

Wound healing in patients with diabetes remains a notable clinical challenge, arising from mitochondrial dysfunction in endothelial cells, which in turn leads to insufficient neovascularization. An effective approach to treating diabetic wounds involves administering exosomes that promote angiogenesis. Exosomes derived from adipose-derived mesenchymal stem cells cultured in a three-dimensional environment (3D-Exo) surpass conventional exosomes in yield, quality, and functionality, offering promising potential for diabetic wound healing. The synergistic promotion of wound repair by a multifunctional 3D-Exo-loaded hybrid scaffold has rarely been reported, and the mechanism underlying their combinatorial effect remains unclear. Herein, direct-writing melt electrospinning (DME) was employed to fabricate a novel polycaprolactone (PCL) microfiber scaffold (DME scaffold, DMEs), integrated with gelatin methacryloyl (GelMA) and 3D-Exo. Characterization of DMEs + GelMA@3D-Exo was subsequently performed. In vitro, the hybrid scaffold demonstrated biocompatibility with human umbilical vein endothelial cells and showed potential to facilitate angiogenesis and collagen formation. In vivo, the application of DMEs + GelMA@3D-Exo improved collagen deposition, stimulated angiogenesis, and increased wound closure rates, surpassing those observed in the DMEs and DMEs + GelMA groups. The underlying

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Mesenchymal Stem CellsWound HealingHumansAnimalsTissue ScaffoldsNeovascularization, PhysiologicExosomesHuman Umbilical Vein Endothelial CellsAngiogenesisMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research